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Abstract 21 
Optineurin (OPTN) is a multifunctional protein involved in autophagy, secretion as well as 22 
NF-κB and IRF3 signalling and OPTN mutations are associated with several human 23 
diseases. Here we show that, in response to viral RNA, OPTN translocates to foci in the 24 
perinuclear region, where it negatively regulates NF-κB and IRF3 signalling pathways and 25 
downstream pro-inflammatory cytokine secretion. These OPTN foci consist of a tight cluster 26 
of small membrane vesicles, which are positive for ATG9A. Disease mutations linked to 27 
POAG cause aberrant foci formation in the absence of stimuli, which correlates with the 28 
ability of OPTN to inhibit signalling. Using proximity labelling proteomics, we identify the 29 
LUBAC complex, CYLD and TBK1 as part of the OPTN interactome and show that these 30 
proteins are recruited to this OPTN-positive perinuclear compartment. Our work uncovers a 31 
crucial role for OPTN in dampening NF-κB and IRF3 signalling through the sequestration of 32 
LUBAC and other positive regulators in this viral RNA-induced compartment leading to 33 
altered pro-inflammatory cytokine secretion. 34 
 35 
Summary Statement 36 
Disease-associated OPTN mutations impact the formation of a viral RNA-induced 37 
compartment, which is important for regulating NF-κB and IRF3 signalling and pro-38 
inflammatory cytokine secretion.  39 
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Introduction 40 
Pathogen associated molecular patterns (PAMPs) are recognised by pattern recognition 41 
receptors (PRRs), such as Toll-like receptors (TLRs), and trigger a range of adaptive and 42 
innate immune responses in the host (Takeuchi and Akira, 2010). For example, activation of 43 
TLR3 or RIG-I by double-stranded viral RNA activates signalling cascades culminating in the 44 
activation of transcription factors including NF-κB and IRF3 and gene expression programs 45 
composed of pro-inflammatory cytokines (e.g. IL6) and interferons (IFNs) respectively 46 
(Alexopoulou et al., 2001). Optineurin (OPTN) appears to be a key protein in a range of 47 
pathways downstream of TLR3, participating in the innate immune response through the 48 
secretion of cytokines, acting as a selective autophagy receptor, and regulating both NF-κB 49 
as well as IRF3 signalling (Slowicka et al., 2016). 50 
NF-κB signalling centres around the NF-κB transcription factor complex which, under non-51 
stimulated conditions, is inhibited through binding to IκB proteins. In response to stimuli such 52 
as TLR3 or RIG-I ligation, the pathway is switched on leading to activation of the IKK 53 
complex, composed of two kinase subunits (IKKα and IKKβ) and a regulatory subunit IKKγ 54 
(NF-κB essential modulator [NEMO]), which phosphorylates IκB proteins and triggers their 55 
subsequent degradation. This degradation releases the NF-κB complex, allowing it to 56 
translocate to the nucleus and induce expression of numerous target genes (Perkins, 2007). 57 
An additional critical step in this pathway is the linear M1-linked ubiquitination of NEMO and 58 
receptor-interacting protein kinase 1 (RIPK1) by the linear ubiquitin assembly complex 59 
(LUBAC), which consists of HOIP (RNF31), HOIL-1L (RBCK1) and SHARPIN (Gerlach et 60 
al., 2011; Kirisako et al., 2006; Tokunaga et al., 2009; Tokunaga et al., 2011). These linear 61 
ubiquitin chains can then function as scaffolds to recruit the IKK complex through the 62 
ubiquitin binding in ABIN and NEMO (UBAN) domain of the IKK subunit NEMO (Fujita et al., 63 
2014; Rahighi et al., 2009; Wagner et al., 2008). OPTN is highly similar to NEMO with 64 
around 52% sequence homology and sharing its linear ubiquitin-binding UBAN domain 65 
(Schwamborn et al., 2000; Wagner et al., 2008). However, unlike NEMO, OPTN cannot bind 66 
to IKKα or IKKβ and therefore cannot rescue NF-κB activity in NEMO-deficient cells 67 
(Schwamborn et al., 2000). Instead, OPTN appears to antagonise NEMO function by 68 
competitively binding to ubiquitinated RIPK1 and can thereby inhibit TNFα-induced NF-κB 69 
activation (Zhu et al., 2007). In addition, OPTN interacts with CYLD, a deubiquitinase (DUB) 70 
for linear and K63 ubiquitin chains, which is able to negatively regulate NF-κB signalling via 71 
the deubiquitination of a range of NF-κB signalling proteins including NEMO and RIPK1 72 
(Lork et al., 2017; Nagabhushana et al., 2011). 73 
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Alternatively, OPTN can bind to the IKK-related kinase TBK1 or the E3 ligase TRAF3 to 74 
regulate IRF3 activity (Mankouri et al., 2010; Morton et al., 2008). A complex composed of 75 
TBK1 and IKKε is activated via TRAF3 downstream of PRRs, such as TLR3 or RIG-I. Once 76 
active, the TBK1/IKKε complex can phosphorylate its substrate, IRF3, which subsequently 77 
dimerises and translocates to the nucleus to induce expression of target genes such as Type 78 
I IFNs (IFNs). Through its interactions with both TBK1 and TRAF3, OPTN appears to 79 
attenuate IFN-β production (Mankouri et al., 2010). 80 
An increasing number of perturbations in OPTN gene function have been linked to diseases 81 
including primary open-angle glaucoma (POAG), amyotrophic lateral sclerosis (ALS), 82 
Paget’s disease of bone (PDB) and Crohn’s disease (CD) (Albagha et al., 2010; Maruyama 83 
et al., 2010; Rezaie et al., 2002; Smith et al., 2015). A common feature of OPTN’s role in 84 
these diseases appears to be aberrant NF-κB signalling or cytokine secretion profiles. Many 85 
ALS mutants show a loss of OPTN-mediated NF-κB suppression (Nakazawa et al., 2016), 86 
deficiencies in OPTN expression increase NF-κB activity and susceptibility to PDB (Obaid et 87 
al., 2015), and a subset of CD patients with reduced OPTN expression display impaired 88 
secretion of TNF-α, IL6 and IFN-γ (Smith et al., 2015). 89 
In this study, we address the role of OPTN in innate immune signalling and cytokine 90 
secretion and the mechanism by which perturbation of OPTN function in these processes 91 
may contribute to human inflammatory disease. We use a retinal pigment epithelial (RPE) 92 
cell model, which is relevant to the role of OPTN in the pathogenesis of POAG, and show 93 
these cells respond to TLR3 and RIG-I ligands, leading to upregulation of OPTN and its 94 
translocation to perinuclear foci. Our ultrastructural analysis of these foci by correlative light 95 
and electron microscopy reveals that this compartment consists of a tight cluster of small 96 
vesicles, which appear positive for the autophagy protein ATG9A. This multispanning 97 
membrane protein is present at the Golgi complex and in clusters of small 30-40 nm 98 
vesicles, which are often found in close proximity to autophagosomes, but do not appear to 99 
be incorporated into the growing phagophore (Orsi et al., 2012; Young et al., 2006). We 100 
demonstrate that wild-type or mutant variants of OPTN show variable recruitment to this 101 
vesicle cluster, which correlates with its ability to negatively regulate NF-κB and IRF3 102 
signalling and therefore cytokine secretion. Using proximity-dependent proteomics (BioID) to 103 
characterise this compartment, we identify novel OPTN interacting proteins including IFT74, 104 
IFI35, a phosphoinositide phosphatase complex (MTMR6-MTMR9) and LUBAC, with the 105 
latter being recruited to OPTN-positive foci upon TLR3 ligation. Our data suggests that 106 
OPTN can inhibit the innate immune response through sequestering key components of NF-107 
κB and IRF3 signalling pathways in a novel perinuclear compartment. Disease-associated 108 
OPTN mutations impact on the formation of the perinuclear compartment and result in hypo- 109 
 5 
or hyper-activation of the immune response, which could potentially drive the development of 110 
a number of human diseases.  111 
 6 
Results 112 
Retinal pigment epithelial (RPE) cells exhibit a robust response to double-stranded 113 
RNA 114 
RPE cells perform a number of support functions in the inner eye including the secretion of 115 
signalling molecules and the maintenance of the immune privileged environment through 116 
communication with the immune system (Detrick and Hooks, 2010). Previous reports have 117 
demonstrated that RPE cells express a number of TLRs including the viral RNA receptor, 118 
TLR3 (Kumar et al., 2004). OPTN mutations have been implicated in POAG (Kumar et al., 119 
2016; Rezaie et al., 2002), making the RPE cell line a relevant tool to study OPTN function 120 
in this disease. Furthermore, the proposed roles for OPTN in anti-viral immunity and TLR3 121 
signalling led us to investigate the utility of this cell line as a tractable human model for 122 
OPTN function in these pathways. 123 
RPE cells were stimulated with a range of PAMPs and the immune response determined 124 
through the quantification of CXCL8 secretion. Of all the PAMPs tested, only poly(I:C) and 125 
pppRNA induced significant CXCL8 secretion consistent with the expression and activation 126 
of TLR3 and RIG-I in RPE cells (Fig. 1A). Lipopolysaccharide (LPS), Pam3CSK4 and 2’,3’-127 
cGAMP (cGAMP) were unable to elicit the release of CXCL8 from RPE cells illustrating a 128 
lack of activation downstream of TLR4, TLR2 and STING. To determine the complete 129 
secretory response of RPE cells downstream of poly(I:C) stimulation, we analysed 130 
conditioned medium from unstimulated or poly(I:C)-stimulated RPE cells using quantitative 131 
SILAC mass spectrometry. These experiments identified 380 proteins in the conditioned 132 
medium with 26 showing significant (p<0.05) upregulation (Fig. 1B, Table S1). Among the 133 
upregulated proteins were well-known pro-inflammatory cytokines such as CXCL8 and, to a 134 
lesser extent, IL6 (Fig. 1B). We validated this data by ELISA and found poly(I:C) stimulation 135 
resulted in the induction of both CXCL8 and IL6 protein secretion (Fig. 1C[i,ii]). To assess 136 
the contribution of NF-κB signalling in regulation of cytokine secretion, we generated an RPE 137 
cell line expressing a NF-κB luciferase reporter. We found that stimulating these cells with 138 
poly(I:C) induced NF-κB promoter activity and a similar elevation in phospho-NF-κB p65 was 139 
observed using immunoblot analysis (Fig. 1C[iii],D). Although no IFNs were detected in the 140 
proteomics datasets, we predicted that IRF3 signalling would also be active downstream of 141 
TLR3 (Doyle et al., 2002). Indeed, upon poly(I:C) stimulation we observed a rapid 142 
phosphorylation of IRF3, an elevation in IFN-β mRNA levels, and could detect IFNs in the 143 
supernatant 2 hours post stimulation (Fig. 1C[iv-v],D). 144 
OPTN translocates to a novel perinuclear compartment in response to double-145 
stranded RNA 146 
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Transient overexpression of OPTN triggers the formation of Golgi-proximal foci (Mao et al., 147 
2017; Maruyama et al., 2010; Nagabhushana et al., 2010; Park et al., 2006; Park et al., 148 
2010; Shen et al., 2011; Turturro et al., 2014; Ying et al., 2010), which have been postulated 149 
to be aggresomes (Mao et al., 2017) or organelles participating in post-Golgi membrane 150 
trafficking and the maintenance of Golgi integrity (Nagabhushana et al., 2010; Park et al., 151 
2006; Park et al., 2010). We observed that stably expressed GFP-OPTN was predominantly 152 
cytosolic in resting RPE cells but, strikingly, translocated to perinuclear foci after stimulation 153 
with both poly(I:C) or pppRNA (Fig. 2A,B), but not with other PAMPs, such as LPS, cGAMP 154 
or Pam3CSK4 (Fig. S1A). Similarly, endogenous OPTN was recruited from a diffuse 155 
cytosolic pool to bright foci in the perinuclear region in poly(I:C)-stimulated RPE cells (Fig. 156 
2C). We assessed the rate of formation of this compartment and discovered that the foci 157 
began to form beyond 2 hours post-stimulation before peaking at approximately 24 hours 158 
(Fig. 2D). OPTN gene expression is regulated through NF-κB signalling (Sudhakar et al., 159 
2009) and increases upon TLR3 activation by poly(I:C) or viral infection (Mankouri et al., 160 
2010). Similarly, we observed that expression of OPTN is markedly upregulated in response 161 
to poly(I:C) stimulation in RPE cells with kinetics similar to foci formation (Fig. 2E). This data 162 
suggests that elevated OPTN expression triggers its accumulation into perinuclear foci.  163 
To further analyse the nature of this perinuclear OPTN-positive compartment, we labelled 164 
GFP-OPTN expressing cells with a variety of organelle markers. The foci showed very little 165 
overlap with markers of the endocytic pathway including EEA1 and LAMP1 (Fig. S1B[i,ii]). 166 
Notably, the foci could be observed in close proximity to, but only showed partial 167 
colocalisation with the trans-Golgi marker TGN46, the cation-independent mannose-6-168 
phosphate receptor or the autophagosomal membrane marker LC3 (Fig. 2F[i], S1B[iii,iv]). 169 
Further observations indicated strong colocalisation with the OPTN-binding partner MYO6 170 
(Fig. S1C) and with the Golgi SNARE VTI1A, (Fig. 2F[ii],G) suggesting some continuation 171 
with the Golgi complex. Depletion of MYO6 by siRNA had no effect on the formation of the 172 
foci indicating that the recruitment of OPTN to these structures and the formation of the foci 173 
was not dependent on MYO6 (Fig. S1D). 174 
TBK1 activity is necessary for OPTN recruitment to foci but not their long-term 175 
stability 176 
Given the well-established role of TBK1 and OPTN in the antiviral response (Pourcelot et al., 177 
2016), we next assessed the role of TBK1 in foci formation. TBK1 activity measured through 178 
the increase in phosphorylation (p-TBK1) was evident 30 mins post-TLR3 stimulation and 179 
returned to baseline levels after 8 hours (Fig. 3A). Using a specific inhibitor of TBK1, BX795, 180 
OPTN foci formation could be abolished in a dose-dependent fashion downstream of TLR3 181 
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activation (Fig. 2H,I). Interestingly, addition of BX795 six hours after poly(I:C) stimulation did 182 
not influence foci formation (Fig. 3B,C), which indicates that TBK1 kinase activity is required 183 
for initiation of the foci but is dispensable for the subsequent maintenance of the structure. 184 
OPTN disease mutants show perturbed foci formation 185 
Previous work has linked the OPTN E50K mutant to POAG and has shown that OPTN 186 
overexpression causes the formation of large perinuclear foci in cells (Nagabhushana et al., 187 
2010; Park et al., 2006; Park et al., 2010; Rezaie et al., 2002; Turturro et al., 2014). 188 
Conversely, the E478G mutation, which is linked to ALS, appears to lack this capacity 189 
(Maruyama et al., 2010; Turturro et al., 2014). We predicted that these mutants might show 190 
a perturbed ability to form foci in response to poly(I:C) stimulation. Strikingly, ~95% of RPE 191 
cells expressing GFP-OPTN E50K exhibited a constitutive formation of this compartment 192 
even in the absence of stimuli, compared to around 5% of cells expressing wild-type GFP-193 
OPTN (Fig. 4A,B). TLR3 stimulation resulted in ~80% of wild-type GFP-OPTN expressing 194 
cells making foci, whereas stimulation had minimal effect on the GFP-OPTN E50K cells that 195 
retained foci in ~95% of cells. By contrast, cells expressing GFP-OPTN E478G were 196 
completely unable to generate foci even after 24 hours of poly(I:C) stimulation (Fig. 4A,B). 197 
Interestingly, although foci formation is triggered by TLR3-stimulation the receptor was not 198 
recruited into OPTN foci suggesting that this compartment is distinct from the route of 199 
receptor trafficking (Fig. S2A). Furthermore, perturbation of TLR3 expression using CRISPRi 200 
largely blocked poly(I:C)-induced OPTN foci formation indicating that this phenotype is 201 
dependent on TLR3 receptor-driven signalling (Fig. S2B-D).  202 
To visualise the nature and further define the composition of the OPTN-positive 203 
compartment, we performed correlative light electron microscopy (CLEM) on foci generated 204 
by the OPTN E50K mutant. Cells were first imaged by confocal microscopy to determine the 205 
localisation of the GFP-OPTN E50K-positive foci and then processed for electron 206 
microscopy. CLEM images showed that the foci were composed of tightly-packed small 207 
membrane vesicles contained within a spherical area void of any further delimiting 208 
membrane (Fig. 4C). As aggresomes are typically membrane-less, electron dense structures 209 
(Kopito, 2000), our data would appear to rule out the possibility that OPTN foci are simply 210 
protein inclusions, but are clearly a membranous compartment consisting of a cluster of 211 
small vesicles of uniform size. 212 
OPTN-positive vesicle clusters colocalise with ATG9A 213 
ATG9A has been implicated in the innate immune response to cytosolic DNA where it 214 
regulates the assembly of STING and TBK1 on a vesicular Golgi-associated perinuclear 215 
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compartment (Saitoh et al., 2009). To determine whether the cellular response to viral RNA 216 
involves a similar ATG9A compartment, we determined whether the OPTN-positive vesicles 217 
colocalise with ATG9A. In unstimulated RPE cells, ATG9A is present at the Golgi complex, 218 
however, after poly(I:C) stimulation the newly formed GFP-OPTN foci are positive for ATG9A 219 
(Fig. 5A-C). Observations of OPTN mutants revealed that GFP-OPTN E50K appeared to 220 
trap ATG9A on Golgi-proximal foci even in the absence of stimuli, while GFP-OPTN E478G 221 
failed to colocalise with ATG9A even after stimulation (Fig. 5A-C). High resolution 222 
microscopy reveals the presence of distinct ATG9A-vesicle clusters appearing to decorate 223 
the OPTN-positive foci. Interestingly, the OPTN-positive foci are occasionally in close 224 
proximity but show only limited overlap with LC3-positive autophagosomes (Fig. S1B). 225 
Furthermore, the poly(I:C) induced ATG9A-positive foci show very little overlap with LC3-226 
positive membranes, confirming previous data that the ATG9A-vesicles might interact with 227 
but do not appear to be incorporated into the growing phagophore (Orsi et al., 2012; 228 
Karanasios et al., 2016) (Fig. 5D). 229 
BioID reveals novel OPTN partners and foci proteins 230 
To gain further insight into both OPTN function and the composition of the foci, we 231 
determined the OPTN interactome using in situ proximity labelling. We generated RPE 232 
stable cell lines expressing full-length OPTN tagged at the N- or C-terminus with the 233 
promiscuous biotin ligase, BirA R118G (BirA*). Expression of the BirA*-OPTN or OPTN-234 
BirA* fusion proteins was verified by immunoblotting and the localisation assessed by 235 
immunofluorescence (Fig. S3A,B). After labelling with biotin overnight, we performed 236 
streptavidin pulldowns and identified enriched proteins by mass spectrometry. Replicates 237 
were analysed against a bank of 5 BirA* only RPE1 control pulldowns using the online tool at 238 
Crapome.org and using a threshold FC-B score of ≥3, we identified 25 significantly enriched 239 
proteins (Table S2) (Mellacheruvu et al., 2013). Among the proteins we identified were a 240 
number of known OPTN-interacting proteins and complexes such as TBK1, CYLD, 241 
TBC1D17, and the LUBAC component HOIP (RNF31) in addition to novel putative 242 
interactors such as the myotubularin-related (MTMR) lipid phosphatase complex 243 
components MTMR6 and 9, intraflagellar transport 74 (IFT74) and Interferon Induced Protein 244 
35 (IFI35) (Fig. 6A,B). 245 
We screened a selection of these candidates for their ability to localise to GFP-OPTN E50K-246 
induced foci (Fig. 6C) including p-TBK1, which has been shown previously to colocalise with 247 
OPTN (Fig. 6C[i]) (Mankouri et al., 2010). Interestingly, the E3 ligase, HOIP, as well as the 248 
DUB, CYLD, both showed colocalisation on OPTN foci, although CYLD only showed 249 
recruitment in a small subpopulation of cells (Fig. 6C[ii,iii]). In contrast, MTMR6, IFT74 and 250 
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IFI35 showed little recruitment to OPTN foci (Fig. 6C[iv-vi]), and might interact with OPTN 251 
within other cellular pathways such as autophagy. 252 
The linear ubiquitin assembly complex (LUBAC) is recruited to OPTN foci 253 
NEMO interacts with, and is linearly ubiquitinated by, LUBAC to induce the activation of the 254 
IKK complex (Rahighi et al., 2009; Tokunaga et al., 2009). OPTN also binds LUBAC 255 
components HOIP and HOIL-1L and regulates the interaction of RIPK1 and NEMO with the 256 
TNF receptor (TNFR) complex in response to TNF-α (Nakazawa et al., 2016). Our BioID 257 
experiments are consistent with the concept that HOIP interacts with OPTN but also indicate 258 
a possible corecruitment to OPTN foci. Furthermore, the potential cooperation of HOIP and 259 
OPTN in TLR3 signalling remains unexplored. 260 
We investigated the role of LUBAC at OPTN foci by assessing recruitment of HOIP to wild-261 
type GFP-OPTN foci. Initially, HOIP showed a low level of colocalisation with OPTN in 262 
unstimulated cells; however, poly(I:C) stimulation led to the recruitment of HOIP to GFP-263 
OPTN positive vesicles and an elevation in colocalisation (Fig. 7A,B). Quantification of the 264 
colocalisation demonstrated that unstimulated cells expressing the GFP-OPTN E50K mutant 265 
showed much higher HOIP recruitment than wild-type GFP-OPTN even after wild-type GFP-266 
OPTN cells were treated with poly(I:C) (Fig. 7B). Next, we tested whether other components 267 
of the LUBAC complex were also recruited to the OPTN-positive foci and found that upon 268 
TLR3 stimulation both SHARPIN and HOIL-1L showed strong colocalisation (Fig. 7C). To 269 
confirm the interaction between OPTN and HOIP, we performed GFP immunoprecipitations 270 
from HEK293T transiently transfected with wild-type, E50K or E478G GFP-OPTN and HA-271 
HOIP. Wild-type and E50K of GFP-OPTN coimmunoprecipitated HA-HOIP, but GFP-OPTN 272 
E478G, which completely lacks foci, failed to do so (Fig. 7D).  273 
We assessed the contribution of HOIP (and LUBAC) to NF-κB signalling upon TLR3 274 
activation in RPE cells. Depletion of HOIP by siRNA diminished poly(I:C)-induced NF-κB 275 
luciferase activity and secretion of CXCL8 and IL6 (Fig. 7E[i-iv]), confirming that HOIP plays 276 
a critical role in NF-κB activation downstream of TLR3 in these cells. This data suggests that 277 
OPTN can sequester positive regulators of NF-κB signalling in perinuclear foci. 278 
OPTN foci formation and stabilisation require ubiquitination 279 
The presence of LUBAC on OPTN foci implied the presence of linear ubiquitin chains on this 280 
compartment. Indeed, the OPTN E478G mutant, which is characterised by its inability to 281 
bind ubiquitin (Wild et al., 2011) or HOIP, is no longer able form foci (Fig. 4A). To ascertain 282 
the role of ubiquitin on this compartment we labelled poly(I:C)-induced OPTN foci with an 283 
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antibody against ubiquitin (FK2), which recognises a variety of chain types including linear 284 
(Emmerich and Cohen, 2015). In unstimulated cells, antibody staining was very weak and 285 
nuclear but after poly(I:C) treatment the ubiquitin FK2 signal was present on GFP-OPTN and 286 
ATG9A-positive foci (Fig. 7G). Further triple labelling revealed that OPTN and ATG9A or 287 
OPTN and ubiquitin (FK2)-positive compartments also contained HOIP (Fig. S4A). OPTN 288 
has a ubiquitin binding domain that is homologous to NEMO and which binds to linear 289 
ubiquitin chains. We cloned a previously described probe composed of 3 tandem repeats of 290 
the NEMO UBAN domain (RFP-3xUBAN), which shows a 100-fold specificity for M1-linked 291 
linkages over other chain types (van Wijk et al., 2012). This probe was recruited to the 292 
perinuclear foci upon poly(I:C) stimulation and could be blocked by introduction of the F312A 293 
point mutation known to abolish ubiquitin binding (Fig. S4B). The presence of ubiquitin 294 
chains, LUBAC, OPTN and the 3xUBAN probe on the foci prompted us to investigate 295 
whether NEMO itself was also recruited. Indeed, poly(I:C) treatment of RPE cells stably 296 
expressing HA-tagged NEMO triggered its recruitment to OPTN foci (Fig. 7F). The presence 297 
of both LUBAC and NEMO on these OPTN-positive foci is highly suggestive of a regulatory 298 
role in NF-κB signalling by sequestering these components downstream of TLR3. 299 
Despite the requirement for ubiquitin binding in the recruitment of OPTN as demonstrated by 300 
the E478G mutant, siRNA depletion of HOIP had little effect on OPTN relocalisation to foci 301 
(Fig. S4C), and suggests that OPTN recruitment is not solely dependent on LUBAC-302 
synthesised linear ubiquitin. As the OPTN UBAN domain is capable of binding to both K63-303 
linked and linear ubiquitin, but not to K48-linked ubiquitin (Nakazawa et al., 2016), we 304 
hypothesised other chain types might also be present. Expression of a ubiquitin mutant 305 
construct containing a single lysine residue at K63 was also present on the foci, indicating 306 
they are likely to be a mixture of both linear and K63 chains (Fig. S4D), and thus it is 307 
possible that K63 chains are sufficient for the initial recruitment of OPTN. 308 
OPTN foci formation correlates with innate immune signalling and cytokine secretion 309 
The rate of foci formation correlated well with time courses for both the induction of cytokine 310 
secretion and the inhibition of NF-κB or IRF3 signalling. In addition, the presence of multiple 311 
regulators of NF-κB and IRF3 signalling (LUBAC, NEMO and TBK1) suggested a link 312 
between OPTN-induced foci and regulation of these signalling pathways. Previous work has 313 
shown that OPTN is a negative regulator of NF-κB and IRF3 signalling and that ALS 314 
mutations or loss of ubiquitin binding perturb these functions (Mankouri et al., 2010; 315 
Nakazawa et al., 2016). Therefore, we investigated NF-κB activity in parental RPE cells or 316 
RPE cells expressing E50K or E478G and observed a negative correlation between NF-κB 317 
activation and OPTN foci formation. Cells expressing GFP-OPTN E50K markedly inhibited 318 
NF-κB activity and GFP-OPTN E478G cells showed elevated activity relative to non-319 
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expressing control cells (Fig. 8A). Next, we assessed the effect of these mutations on 320 
cytokine secretion downstream of NF-κB signalling. RPE cells overexpressing GFP-OPTN 321 
E50K showed a reduction in CXCL8 and IL6 secretion, whereas OPTN E478G cells 322 
displayed a dramatic increase in secretion of both (Fig. 8B,C). Notably, basal secretion of 323 
CXCL8 and IL6 are also elevated in OPTN E478G cells (Fig. S5C,D). These results were 324 
consistent with data obtained by immunoblotting (Fig. 8D). 325 
As RIG-I stimulation with pppRNA also induced OPTN foci formation, we next investigated 326 
whether OPTN regulated cytokine secretion in this context. As with TLR3-stimulation, the 327 
E50K mutant reduced CXCL8 and IL6 secretion in response to pppRNA, while the converse 328 
is true for the E478G mutant (Fig. S5A,B). Thus, OPTN appears to regulate the innate 329 
immune response to viral RNA generally.  330 
Since OPTN has also been implicated in IRF3 signalling, we next determined the impact of 331 
OPTN mutations on this pathway. We investigated the activity of this pathway in mutant cells 332 
lines and, again, found that overexpression of the OPTN E50K mutant blunted the IRF3 333 
response, as determined by p-IRF3 immunoblot and IFNα/β release assays (Fig. 8D,E). 334 
Conversely, the OPTN E478G mutant showed high levels p-IRF3 prior to stimulation, which 335 
remained elevated, and a concomitant increase in IFNα/β secretion (Fig. 8D,E). Thus, the 336 
propensity to form foci correlates well with NF-κB and IRF3 signalling output and appears to 337 
indicate that the formation or presence of foci is refractory to both signalling pathways.  338 
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Discussion 339 
In order to establish an appropriate immune response and prevent chronic inflammation cells 340 
must tightly regulate innate immune signalling and cytokine secretion. The central role of 341 
OPTN in negatively regulating these signalling pathways is becoming increasingly clear and 342 
different mutations, which modify the ability of OPTN to modify these pathways, appear to 343 
lead to distinct diseases. Here we establish an RPE cell model to investigate the role of 344 
OPTN in innate immune signalling. Using this system, we show that OPTN translocates to 345 
Golgi-proximal foci in response to exogenous RNA and that this compartment negatively 346 
regulates downstream signalling responses. Expression of different disease-causing OPTN 347 
mutants leads to either constitutive foci formation in the absence of stimulation, and a 348 
concurrent attenuation of IRF3 and NF-κB signalling and cytokine secretion, or the converse. 349 
Our ultrastructural characterisation of the OPTN-positive foci reveals that they are not 350 
aggresomes as previously suggested (Mao et al., 2017), but clusters of tightly packed small 351 
vesicles of around 30-40 nm. This vesicle cluster is concentrated in a concise space despite 352 
lacking an outer limiting membrane. Our double-labelling experiments suggest that the 353 
OPTN foci overlap with ATG9A, a transmembrane protein with a key role in autophagy. 354 
ATG9A has a very dynamic trafficking itinerary cycling between the Golgi complex, the 355 
endocytic pathway (Noda, 2017). The exact role of ATG9A remains to be established, 356 
however, it has previously been shown to be important during autophagosome biogenesis 357 
and maturation (Yamamoto et al., 2012). Our results show only a partial colocalization 358 
between ATG9A and LC3, a marker for autophagosomal membranes. This result, although 359 
surprising, is supported by previous findings that show that ATG9A only transiently 360 
associates with the phagophore initiation site (Orsi et al., 2012; Karanasios et al., 2016). 361 
Thus, OPTN might regulate post-Golgi trafficking and sorting of ATG9A-containing vesicles 362 
to the phagophore. In addition, as a selective autophagy receptor, OPTN may control the 363 
spatiotemporal recruitment of ATG9A vesicles to the site of autophagosome formation. This 364 
agrees with the recent finding that autophagy receptors cooperate with TBK1 to recruit the 365 
ULK1 complex to initiate autophagosome formation (Vargas et al., 2019). Therefore, the 366 
OPTN-positive foci could be a compartment that accumulates post-Golgi trafficking 367 
intermediates or marks the site of autophagosome biogenesis.  368 
Our work also highlights the correlation between the formation of OPTN foci and the role of 369 
OPTN in negatively regulating NF-κB and IRF3 signalling. Our data demonstrates that OPTN 370 
expression is upregulated in poly(I:C)-stimulated RPE cells and occurs with kinetics similar 371 
to those of both NF-κB inactivation and OPTN foci formation. Furthermore, we were able to 372 
identify and localise several key mediators of NF-κB and IRF3 signalling to OPTN foci, 373 
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including TBK1, NEMO, CYLD and components of the LUBAC complex. At first sight OPTN 374 
foci formation and IRF3 regulation do not seem to correlate, as p-IRF3 and its activator p-375 
TBK1 are maximal during the first two hours post poly(I:C) stimulation, which was much 376 
earlier than the elevation in visible foci. Data presented here suggests that OPTN migration 377 
to the foci is pivotal in the regulation of IRF3 and immune activation. The loss of foci caused 378 
by expression of the OPTN E478G mutant resulted in IRF3 hyperactivation and the opposite 379 
was seen with expression of the foci forming OPTN E50K. One possibility is that OPTN may 380 
form smaller clusters during the early stages of an immune response that aggregate to form 381 
the visible foci at later timepoints. Nevertheless, if they do form it seems likely that they 382 
require OPTN binding to Ub and the kinase activity of TBK1 to inhibit the immune response, 383 
as blocking both results in the hyper activation of IRF3 downstream of TLR3 activation.   384 
In addition to physically sequestering signalling molecules, the foci could also be involved in 385 
actively switching off TLR3 signalling. The foci resident deubiquitinase CYLD has previously 386 
been shown to target NEMO and RIPK1 resulting in the inhibition of TNFa-induced NFkB 387 
activation in process a dependent on OPTN expression (Nagabhushana et al., 2011). It is 388 
possible that this process occurs in the OPTN foci during a TLR3 stimulated immune 389 
response. Finally, the presence of both ATG9A and LC3 at some OPTN foci could indicate 390 
that autophagy is utilized to regulate the TLR3 immune response, but further work would be 391 
needed to support this notion. Taken together, this data suggests a model in which NF-κB 392 
signalling generates a negative feedback mechanism to prevent excessive signalling via 393 
upregulation of OPTN expression. We propose that the expression of OPTN is tied to its 394 
propensity to oligomerise via dimer or tetramerisation or polyubiquitin chain binding leading 395 
to foci formation, sequestration of NF-κB or IRF3 signalling machinery and the inhibition of 396 
further signalling, possibly via deubiquitination and autophagy. The OPTN E50K mutant 397 
displays a heightened propensity to form oligomers (Li et al., 2016), and this property may 398 
explain the observed constitutive foci. Alternatively, the loss of ubiquitin binding seen with 399 
the OPTN E478G mutant might prevent foci formation by blocking oligomerisation through 400 
polyubiquitin chain binding. Other disease-associated mutations may also alter the ability of 401 
OPTN to oligomerise or to recruit proteins into foci and lead to perturbed downstream 402 
outputs. 403 
Notably, the OPTN foci described here also show striking similarity to those described in a 404 
number of other situations. In particular, activation of the cGAS-STING pathway by cytosolic 405 
DNA leads to the trafficking of STING from the ER to an ER-Golgi intermediate compartment 406 
(ERGIC), which is also positive for ATG9A (Ishikawa et al., 2009; Saitoh et al., 2009). 407 
Trafficking of STING from the ER to this compartment is required for the induction of IRF3 408 
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signalling, while ATG9A negatively regulates this process (Dobbs et al., 2015; Saitoh et al., 409 
2009). Recent work has also defined a role for STING in the induction of autophagy in 410 
response to cGAMP, cytosolic DNA or DNA viruses and that the ERGIC serves a membrane 411 
source for autophagosome formation in this context (Gui et al., 2019). As an important 412 
mediator of autophagy and innate immune signalling, it is tempting to speculate that OPTN 413 
might participate in an analogous process in response to exogenous dsRNA or RNA viruses. 414 
Other proteins including the NLRP3 inflammasome or OPTN binding partners TRAF3 and 415 
TBK1 have also been found to localise to similar Golgi-proximal perinuclear microsomes 416 
upon stimulation (Chen and Chen, 2018; Pourcelot et al., 2016; van Zuylen et al., 2012), 417 
suggesting that this Golgi-proximal platform might be a common mechanism to regulate 418 
signalling, cytokine secretion and autophagy induction in response to diverse PAMPs. 419 
Materials and Methods 420 
Antibodies, plasmids and reagents 421 
Antibodies used in this study were CIMPR (sc-53146; Santa Cruz; IF 1:50), EEA1 (610457; 422 
BD Biosciences; IF 1:100), EF2 (sc-13004; Santa Cruz; Western blot 1:1000), GFP (A11122; 423 
Life Technologies; Western blot 1:1000), HA (11867423001; Roche; IF 1:400), HA (H9658; 424 
Sigma; Western blot 1:1000), LC3 (M152-3; MBL; IF 1:100), LAMP1 (H4A3; Developmental 425 
Studies Hybridoma Bank, University of Iowa; IF 1:100), myc (05-724; Millipore; Western blot 426 
1:1000, IF 1:200), OPTN (HPA003360; Sigma; IF 1:100), p-IRF3 (4947; Cell Signalling; 427 
Western blot 1:1000), p-p65 (3033; Cell Signalling; Western blot 1:1000), p-TBK1 (5483; Cell 428 
Signalling; 5483; Western blot 1:1000, IF 1:100), TGN46 (AHP500; Bio-Rad; IF 1:100), 429 
ubiquitin (BML-PW8810; Enzo Life Sciences; IF 1:200), vinculin (MAB3574; Millipore; 430 
Western blot 1:1000) and Vti1a (611220; BD Biosciences; IF 1:100). The ATG9A antibody 431 
(ab108338; Abcam; IF 1:100) was a kind gift from Professor Margaret S. Robinson (CIMR). 432 
Rabbit polyclonal antibodies raised against GFP and MYO6 were generated in house as 433 
described previously (Buss et al., 1998). 434 
Cells were treated with poly(I:C) (Enzo Life Sciences) at 10 µg/mL, LPS (Enzo Life 435 
Sciences) at 200 ng/ml, 2’,3’-cGAMP (Invivogen) at 10 µg/mL, Pam3CSK4 (Invivogen) at 10 436 
µg/mL, 5’ triphosphate double stranded RNA (pppRNA) (Invitrogen) at 500 ng/mL and 437 
BX795 (Sigma) at 500 nM. All treatments were for 24 hours unless specified otherwise.  438 
GFP-OPTN pEGFPC2 has been described previously (Sahlender et al., 2005) and was 439 
subcloned into the pLXIN retroviral packaging plasmid (Clontech) for stable cell line 440 
production. GFP-OPTN E50K and E478G pLXIN mutants were generated by site-directed 441 
mutagenesis. The myc-BirA*-OPTN pLXIN vector was created by subcloning OPTN into the 442 
myc-BirA* pLXIN plasmid described previously (O’Loughlin et al., 2018). For OPTN-BirA*-HA 443 
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pLXIN, BirA* was amplified by PCR, introducing a C-terminal HA tag, and inserted into 444 
pLXIN. OPTN was subcloned into this vector 5’ to the BirA* tag. 445 
HA-Ub K63 pRK5 and NF-κB-TA-LUC-UBC-GFP-W pHAGE were obtained from Addgene 446 
(17606 and 49343 respectively). NEMO, TLR3, CYLD, SHARPIN, HOIP and RBCK1 were 447 
obtained from Addgene (13512, 13641, 15506, 50014, 50015 and 50016 respectively) and 448 
subcloned into pLXIN. Full-length IFT74 was generated by Gibson assembly of MGC clones 449 
8322576 and 6614193 (Dharmacon, GE Healthcare). MTMR6 was obtained from Sino 450 
Biologicals (HG15192) and the IFI35 open reading frame was synthesised as a Gblock from 451 
Integrated DNA technologies. All were subcloned into pLXIN with HA tags. 452 
The CRISPRi lentiviral vector pU6-sgRNA EF1Alpha-puro-T2A-BFP was a kind gift from 453 
Luke Gilbert. Protospacer sequences targeting TLR3 5’-GATTTCATCAGGGAAGTGTG-3’ or 454 
a control non-targeting sequence (GAL4) 5’- GAACGACTAGTTAGGCGTGTA-3’ were 455 
inserted by restriction cloning. 456 
3xUBAN pRFPC3 was generated as a gBlock (Integrated DNA technologies) comprising the 457 
UBAN sequence of NEMO flanked by a 5’ SalI site and 3’ XhoI-BamHI sites. Plasmid DNA 458 
was linearised with XhoI and BamHI and ligated with gBlock DNA digested with SalI and 459 
BamHI. Complementary SalI and XhoI overhangs were ligated, destroying the restriction 460 
sites and leaving a unique XhoI site at the 3’ end of the UBAN open reading frame which 461 
could be used in subsequent cloning steps. This process was repeated 3 times to generate 3 462 
tandem duplicates of the UBAN sequence. 463 
Cell lines and transfection  464 
RPE (hTERT RPE-1 (ATCC® CRL-4000™)) cells were cultured in DMEM:F12-HAM (Sigma) 465 
mixed in a 1:1 ratio and supplemented with 10% FBS (Sigma), 2 mM L-glutamine (Sigma), 466 
100 U/ml penicillin and 100 µg/ml streptomycin (Sigma). HEK293T and Phoenix cells were 467 
cultured in DMEM containing GlutaMAX (Thermo Fisher Scientific) and supplemented with 468 
10% FBS and 100 U/ml penicillin and 100 µg/ml streptomycin.  469 
Stably expressing cell lines were generated using retrovirus or lentivirus produced in the 470 
Phoenix retroviral packaging cell line or HEK293T cells respectively. Cells growing in 100 471 
mm dishes were transfected with 10 µg retroviral transfer vector DNA and 25 µl 472 
Lipofectamine 2000 (Thermo Fisher Scientific) or 8 µg lentiviral transfer vector DNA, 8 µg 473 
pCMV-dR8.91 and 1 µg pMD2.G packaging plasmids using 48 µl TransIT-LT1 (Mirus). 474 
Plasmid DNA was mixed with transfection reagent in Opti-MEM (Thermo Fisher Scientific) 475 
and incubated for 30 minutes before addition to cells. After 48 hours, conditioned medium 476 
was harvested, filtered and added to the relevant cells. Cells were subsequently selected 477 
with 500 µg/ml G418 (Gibco), 1 µg/ml puromycin or sorted by FACS. RPE1 dCas9-KRAB 478 
cells were a kind gift from Ron Vale (University of California). For immunoprecipitation 479 
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experiments, HEK293T cells were transfected in 100 mm dishes using 8 µg plasmid DNA 480 
and 24 µl PEI (Polysciences, Inc). DNA was mixed with PEI in Opti-MEM (Thermo Fisher 481 
Scientific), incubated for 20 minutes and added to cells. For siRNA-mediated gene silencing, 482 
RPE cells were transfected with ON-TARGETplus SMARTpool oligonucleotides 483 
(Dharmacon, GE Healthcare) targeting MYO6 or HOIP using Oligofectamine (Invitrogen). 484 
Cells were transfected on both day 1 and day 3 and assayed on day 5. 485 
For RIG-I stimulation experiments, 1 µg pppRNA (Invivogen) was added to 100 µl LyoVec 486 
(Invivogen), incubated for 15 minutes at RT, transfected into cells at a final concentration of 487 
500 ng/ml, and incubated for 24 hours. 488 
Cytokine assays 489 
Cytokine (IL6 and CXCL8) levels in tissue culture supernatants were determined by ELISA 490 
assay (DY206 and DY208; R&D Systems). All assays were performed according to the 491 
manufacturer’s instructions and read on a CLARIOstar microplate reader (BMG 492 
Labtech).  ELISA data was normalized to viable cell number determined by MTT assay 493 
(Boehringer Ingelheim) or CellTiter-Blue (Promega). IFN levels were determined using a 494 
HEK293T IFN reporter cell line (clone 3C11) which was obtained from Prof. Jan Rehwinkel 495 
(University of Oxford, UK) (Bridgeman et al., 2015). For the IFN assay, IFN reporter cells were 496 
cultured on a 96-well plate with 70 μL DMEM medium overlaid with 30 μL of cell culture 497 
supernatant. After 24 hours, luciferase expression was quantified using a Pierce™ Firefly Luc 498 
One-Step Glow Assay Kit (Thermo Fisher Scientific) according to manufacturer’s instructions 499 
and read on a FLUOstar Omega microplate reader (BMG Labtech).  500 
qPCR 501 
Total RNA was harvested using a RNeasy Mini Kit and RNase-free DNase treatment 502 
(Qiagen), in accordance with the manufacturer's instructions. RNA (1 μg) was converted to 503 
cDNA using oligo d(T) primers and Promega reverse transcription kit. Quantitative real time 504 
PCR (qRT-PCR) was performed in duplicate using a SYBR® Green PCR kit (Qiagen) on a 505 
Mastercycler® ep realplex (Eppendorf) or Quantstudio 7 flex (Life Technologies). The PCR 506 
mix was annealed/extended at 60 °C for 60 seconds, for a total of 40 cycles, then a melting 507 
curve was performed. Primers for HOIP were 5’-AGACTGCCTCTTCTACCTGC-3’ and 5’-508 
CTTCGTCCCTGAGCCCATT-3’, TLR3 set 1 5’-TCAACTCAGAAGATTACCAGCCG-3’ and 509 
5’-AGTTCAGTCAAATTCGTGCAGAA-3’, TLR3 set 2 5’-510 
CAAACACAAGCATTCGGAATCTG-3’ and 5’-AAGGAATCGTTACCAACCACATT-3’ and the 511 
housekeeper gene peptidylprolyl isomerase A (PPIA) 5’-GTGTTCTTCGACATTGCCGT-3’ 512 
and 5’-CCATTATGGCGTGTGAAGTCA-3’ or Actin 5’-GCTACGAGCTGCCTGACG-3’ and 513 
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5’-GGCTGGAAGAGTGCCTCA-3’. Relative expression was compared between groups 514 
using the ΔΔCt method (Livak and Schmittgen, 2001). 515 
Cell lysate preparation 516 
Cells were plated in a 6-well plate and stimulated at ~80% confluent. Cells were washed and 517 
lysed in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 0.5% sodium deoxycholate, 1 mM EDTA, 518 
0.5 mM EGTA, 1% IGEPAL® CA-630, and 0.1% SDS) containing protease inhibitor cocktail 519 
(Roche) and PhosSTOP™ (Sigma). Cell lysates were sonicated and clarified at 20,000 x g for 520 
10 minutes at 4°C. Total protein concentration was measured using a Pierce™ BCA Protein 521 
Assay Kit (Thermo Fisher Scientific) and used to normalise sample loading.  522 
Immunoprecipitation 523 
48 hours post-transfection, cells were lysed with 1% NP-40 lysis buffer (50 mM Tris-HCl pH 524 
7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40) containing complete protease inhibitor cocktail 525 
(Roche), passed repeatedly through a 25G needle to homogenise and clarified by 526 
centrifugation at 20,000 x g for 10 minutes at 4°C. Subsequently, clarified lysates were 527 
incubated with 10 µl of GFP-nanobody Affi-gel resin (O’Loughlin et al., 2018) for 3 hours with 528 
mixing. Beads were washed with 1% NP-40 buffer, then TBS and were eluted in SDS 529 
sample loading buffer at 95°C. 530 
Western blotting 531 
Cell lysates and immunoprecipitations were resolved using precast Novex 4-12% Bis-Tris Midi 532 
Protein Gels (Thermo Fisher Scientific) and transferred to methanol-activated Immobilon-P 533 
PVDF Membranes (Millipore) using a wet transfer system. Membranes were blocked with 5% 534 
BSA (Sigma) or 5% milk in TBS containing 1% Tween-20 and incubated with primary antibody 535 
overnight at 4°C. Membranes were subsequently probed with HRP-conjugated secondary 536 
antibody, washed and bound antibody was detected using enhanced chemiluminescence 537 
(ECL) substrate. 538 
Immunofluorescence 539 
Cells were grown on sterilised coverslips and fixed in 4% formaldehyde. In the case of 540 
structured illumination microscopy experiments, cells were grown on acid-washed, high 541 
performance, No. 1.5 (170±5 µm), 18 mm square coverslips (Schott). Post-fixation cells 542 
were permeabilised in 0.2% Triton X-100 and blocked with 1% BSA. Coverslips were 543 
incubated with primary antibody and then fluorescently-labelled secondary antibodies 544 
(Molecular probes). Hoechst was used to visualise DNA and biotin with AlexaFluor®568-545 
conjugated streptavidin (Molecular probes). Images were acquired on a Zeiss Axioimager 546 
M1, a Zeiss LSM710 confocal microscope, a Zeiss Elyra PS1 super-resolution microscope 547 
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or Thermo Fisher CellInsight CX7 high-content microscope. To measure colocalisation, 548 
images from randomly selected fields were background subtracted and manually segmented 549 
before calculating the Pearson’s correlation coefficient using ImageJ and the coloc2 plugin. 550 
Alternatively, confocal images from randomly selected fields of view were automatically 551 
thresholded using the Costes et al. method (Costes et al., 2004) before calculating the 552 
Pearson’s correlation coefficient using Volocity software v6.3 (PerkinElmer). Counts of 553 
OPTN puncta were performed using the HCS Studio 3.0 software packaged with the Cell 554 
Insight CX7 Microscope and the SpotDetector V4 application. Foci-positive cells were scored 555 
manually. All statistical analysis was performed in GraphPad Prism. 556 
CLEM 557 
Cells were plated on alpha-numeric gridded glass-bottom coverslips (P35G-1.5-14-C-GRID, 558 
MatTek, MA, USA) at ~40-50% confluency and fixed with 2% formaldehyde, 2.5% 559 
glutaraldehyde and 0.1 M cacodylate buffer for 30 minutes at room temperature. The 560 
reaction was quenched with 1% sodium borohydride for 20 minutes and cells were stained 561 
with Hoechst before washing with 0.1 M cacodylate. Cells were imaged on an LSM780 562 
confocal microscope (Zeiss) and the coordinates of cells selected for imaging were 563 
recorded. After confocal image acquisition, cells were secondarily fixed with 1% osmium 564 
tetroxide and 1.5% potassium ferrocyanide before being washed and incubated with 1% 565 
tannic acid in 0.1 M cacodylate to enhance membrane contrast. Samples were washed with 566 
dH2O, dehydrated through an ethanol series (70%, 90%, 100%, and absolute 100%) and 567 
infiltrated with epoxy resin (Araldite CY212 mix, Agar Scientific) mixed at 1:1 with propylene 568 
oxide for one hour, before replacement with neat Epoxy resin. Excess resin was removed 569 
from the coverslip before pre-baked resin stubs were inverted over coordinates of interest 570 
and the resin cured overnight. Stubs were removed from the coverslip by immersing the 571 
coverslip in liquid nitrogen. Areas of interest were identified by alpha-numeric coordinates 572 
and 70 nm ultrathin sections were collected using a Diatome diamond knife attached to an 573 
ultracut UCT ultramicrotome (Leica). Sections were collected onto piloform-coated slot grids, 574 
stained with lead citrate and imaged on a FEI Tecnai Spirit transmission electron microscope 575 
at an operating voltage of 80kV. 576 
NF-κB luciferase assay 577 
NF-κB luciferase reporter cells were plated onto 24-well plates and, at ~80% confluency, 578 
were stimulated with 10 µg/ml poly(I:C) for 6 hours. Cells were washed with PBS, lysed in 579 
100 µl Glo lysis buffer and clarified at 20,000 x g for 10 mins. Clarified supernatants were 580 
mixed 1:1 with ONE-GLO luciferase reagent and luminescence was analysed on a 581 
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CLARIOstar microplate reader (BMG Labtech). To normalise the data, GFP fluorescence of 582 
the clarified supernatant was also determined using the same plate reader. 583 
Secretomics 584 
RPE cells were cultured in SILAC DMEM:F12 (Thermo Fisher Scientific) supplemented 10% 585 
dialysed FBS (Gibco) and the heavy amino acids L-Arginine 13C6 15N4 (147.5 mg/l) and L-586 
Lysine 13C6 15N2 (91.25 mg/l; Cambridge Isotope Laboratories), or equal amounts of light 587 
arginine and lysine (Sigma). Cells were taken through 3 passages to ensure complete 588 
labelling and plated onto 100 mm dishes. At ~80% confluency, cells were incubated for 18 589 
hours in the presence or absence of 10 µg/ml poly(I:C). Subsequently, cells were washed 590 
thoroughly with PBS and serum-free medium and incubated for 6 hours in 10 ml serum-free 591 
medium containing poly(I:C) or vehicle. Conditioned medium was harvested and clarified at 592 
4,000 x g at 4°C. Cell counts were used to normalise loading and equivalent volumes of 593 
heavy and light medium were pooled. The volume of the medium was reduced using low 594 
molecular weight spin concentrators (Sartorius) and the samples were resolved 595 
approximately 1.5 cm into a pre-cast 4-12% Bis-Tris polyacrylamide gel. The lanes were 596 
excised, cut into chunks and the proteins reduced, alkylated and digested in-gel. The 597 
resulting tryptic peptides were analysed by LC-MSMS using a Q Exactive coupled to an 598 
RSLCnano3000 (Thermo Scientific). Peptides were resolved on a 50 cm EASY-spray 599 
column (Thermo Scientific) with MSMS data acquired in a DDA fashion. Spectra were 600 
searched against a Homo sapiens Uniprot reference database in the MaxQuant proteomics 601 
software package (Cox and Mann, 2008). Cysteine carbamidomethlyation set as a fixed 602 
modification and methionine oxidation and N-terminal acetylation as variable modifications. 603 
Peptide and protein false discovery rates (FDRs) were set to 0.01, the minimum peptide 604 
length was set at 7 amino acids and up to 2 missed cleavages were tolerated. Protein 605 
differential abundance was evaluated using the Limma package (Smyth, 2005), within the R 606 
programming environment (R core team, 2017). Differences in protein abundances were 607 
statistically determined using the Student's t-test with variances moderated by Limma's 608 
empirical Bayes method. P-values were adjusted for multiple testing by the Benjamini 609 
Hochberg method (Benjamini and Hochberg, 1995). Gene ontology cellular component 610 
enrichment analysis was performed using the PANTHER online web tool (Mi et al., 2017).  611 
BioID proteomics 612 
BioID experiments were performed as described previously (O’Loughlin et al., 2018). BirA*-613 
OPTN and OPTN-BirA* RPE1 pulldowns were performed in triplicate and duplicate 614 
respectively alongside a set of 5 matched BirA* only RPE1 control pulldowns. OPTN 615 
pulldowns were compared against the BirA* only pulldowns using the online tool at 616 
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CRAPome.org using the default settings and a threshold of ≥3 FC-B was established to 617 
determine candidate OPTN interacting proteins. Data was visualised in Cytoscape and 618 
merged with protein-protein interaction data mined from MIMIx or IMEx curated databases 619 
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Figure legends 847 
Figure 1 – RPE cells show a robust TLR3/RIG-I response. 848 
(A) CXCL8 secretion from RPE cells stimulated with the indicated ligands. Bars depict mean 849 
of ≥n=4 independent experiments ±s.e.m. Statistical significance was calculated by one-way 850 
ANOVA and a Bonferroni post-hoc test. *** = p<0.001. (B) Volcano plot of fold change 851 
versus adjusted p value from SILAC secretome experiments (n=3). Red points are p value 852 
significant (p<0.05) in the poly(I:C) stimulated versus unstimulated condition. Significantly 853 
enriched and other notable proteins are labelled. (C) Poly(I:C)-induced CXCL8 secretion (i), 854 
IL6 secretion (ii), NF-κB-luciferase (iii), IFNa/b secretion (iv) and IFN-β mRNA expression in 855 
RPE cells over the time courses indicated. Bars depict mean of n=4 (i, ii & iv) or n=3 (iii & v) 856 
experiments ±s.e.m. (E) Immunoblot analysis of lysates from RPE cells stimulated with 857 
poly(I:C) for the indicated times and probed with p-p65(Ser536), p-IRF3 and vinculin (loading 858 
control) antibodies. 859 
Figure 2 – OPTN is recruited to a novel compartment in response to single- and 860 
double-stranded viral RNA. (A) Confocal microscope images of RPE cells stably 861 
expressing GFP-OPTN (green) and treated with vehicle, poly(I:C), Lyovec (LV) or pppRNA 862 
transfected with LV for 24 hours. Cells were stained with Hoechst to label DNA (blue). Scale 863 
bar, 20 µm. (B) Percentage of GFP-OPTN cells containing foci after treatment. >100 cells 864 
were manually counted per condition from ³10 randomly selected fields of view. Bars 865 
represent the mean of n=3 independent experiments (except for LV n=2) ±s.e.m. Statistical 866 
significance was determined by repeated measures ANOVA and Bonferroni post-hoc test. 867 
*** = p<0.001. (C) Confocal microscope images of RPE cells stimulated with poly(I:C) for 0 868 
and 24 hours. Cells were immunostained with an anti-OPTN antibody (green) and DNA was 869 
visualised with Hoechst (blue). Scale bar, 20 µm. (D) Foci count/GFP-OPTN cell after 870 
treatment with poly(I:C) for the indicated times. Bars represent mean of n=3 independent 871 
experiments ±s.e.m. Statistical significance was determined by repeated measures ANOVA 872 
and a Bonferroni post-hoc test. * = p<0.05 and ** = p<0.01. (E) Immunoblot analysis of 873 
lysates from RPE cells stimulated with poly(I:C) for indicated times and probed with OPTN 874 
and EF2 (loading control) antibodies. (F) Confocal microscope images of RPE cells stably 875 
expressing GFP-OPTN (green) and treated with poly(I:C) as specified. Cells were 876 
immunostained with an antibody against TGN46 [i] and VTI1A [ii] (red). Scale bars, 20 µm. 877 
(G) Pearson’s correlation coefficient calculated for GFP-OPTN versus VTI1A after treatment 878 
with poly(I:C) for 0 and 24 hours. Bars represent the mean of n=3 independent experiments 879 
±s.e.m. Cells were quantified from ≥20 randomly selected fields of view (1 cell/image). 880 
Statistical significance was calculated using a two-sample t-test. *** = p<0.001. (H) Dose-881 
response curve of foci count/GFP-OPTN cell after treatment with poly(I:C) for 24 hours in 882 
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combination with the indicated dose of BX795. Points represent mean of n=3 experiments 883 
±s.e.m. (I) Confocal microscope images of RPE cells stably expressing GFP-OPTN (green) 884 
and treated with poly(I:C) for 24 hours in combination with DMSO (left panel) or BX795 (right 885 
panel). Scale bar, 20 µm. 886 
Figure 3 – TBK1 inhibition perturbs foci formation. 887 
(A) Left, Immunoblot analysis of lysates from RPE cells stimulated with poly(I:C) for the 888 
indicated times and probed with p-TBK1 and vinculin (loading control) antibodies. Right, 889 
graph depicting gel band density analysis for p-TBK1. Points represent mean of n=3 890 
experiments and error bars indicate SEM. (B) Confocal microscope images of RPE cells 891 
stably expressing GFP-OPTN (green) and treated with vehicle (top row) or poly(I:C) for 24 892 
hours (bottom row). Cells were simultaneously treated with DMSO or BX795 for 18 hours 893 
(added after 6 hours) or 24 hours (added after 0 hours). DNA was visualised with Hoechst 894 
(blue). Scale bar, 20 µm. (C) Relative foci counts/GFP-OPTN cell after treatment with 895 
poly(I:C) for 24 hours combined with BX795 addition after the indicated times. Points 896 
represent mean of n=3 independent experiments ±s.e.m. 897 
 898 
Figure 4 – OPTN disease mutants promote aberrant foci formation. 899 
(A) Widefield microscope images of RPE cells stably expressing GFP-OPTN wild-type (WT), 900 
E50K and E478G (green) and treated for 0 hours or 24 hours with poly(I:C). Cells were 901 
stained with Hoechst to label DNA (blue). Scale bar, 20 µm. (B) Top, schematic cartoon of 902 
OPTN domain structure with mutations highlighted. Bottom, graph depicting the percentage 903 
of GFP-OPTN cells containing foci after 0 or 24 hours of poly(I:C) treatment from n=3 904 
independent experiments ±s.e.m. >100 cells were manually counted per condition from ≥10 905 
randomly selected fields of view. (C) Correlative Light Electron Microscopy (CLEM) 906 
micrographs of RPE cells stably expressing GFP-OPTN E50K. [i] Confocal microscope 907 
image of a cell and [ii] magnification of four GFP-positive foci highlighted by the circled 908 
regions 1, 2, 3 and 4. [iii] Electron micrograph with confocal microscope image of GFP-909 
positive foci superimposed. [iv] Electron micrograph of foci-positive region. Four GFP-910 
positive foci are highlighted by the circled regions 1, 2, 3 and 4 and are magnified in the 911 
corresponding panels 1-4. 912 
Figure 5 – OPTN-positive vesicle clusters colocalise with ATG9A (A) Confocal 913 
microscope images of RPE cells stably expressing GFP-OPTN, E50K or E478G (green) and 914 
treated with poly(I:C) for 0 hours or 24 hours. Cells were immunostained with an ATG9A 915 
antibody (red) and Hoechst to label DNA (blue). Scale bars, 20 µm. (B) Pearson’s correlation 916 
coefficient calculated for GFP-OPTN (WT, E50K or E478G) versus ATG9A after treatment 917 
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with poly(I:C) for 0 and 24 hours. Bars represent the mean of n=3 independent experiments 918 
±s.e.m. Cells were quantified from ³10 randomly selected fields of view. Statistical 919 
significance was determined by repeated measures ANOVA and a Bonferroni post-hoc test. 920 
*** = p<0.001. (C) Structured illumination microscopy image of RPE cell stably expressing 921 
GFP-OPTN E50K (green), immunostained with ATG9A antibody (red) and Hoechst to label 922 
DNA (blue). Scale bar, 10 µm. Lower panels are magnifications of the insets highlighted 923 
above. (D) Confocal microscope images of RPE cells stably expressing GFP-OPTN, (green) 924 
and treated with poly(I:C) for 24 hours. Cells were immunostained with an ATG9A antibody 925 
(red) and LC3 antibody (blue). Scale bar, 15 µm. 926 
 927 
Figure 6 – OPTN BioID reveals novel partners and proteins localised to foci.  928 
(A) Graphs depicting SAINT probability and fold change (FC-B) scores for BirA*-OPTN (top) 929 
and OPTN-BirA* (bottom) pull down experiments. Selected high-confidence OPTN 930 
interactors are labelled. (B) Network diagram of high-confidence OPTN interactors identified 931 
by BioID. Node size corresponds to FC-B score (higher confidence = larger node). Solid 932 
lines indicate interactions identified in this study and dashed lines interactions imported from 933 
publicly available protein-protein interaction databases. (C) Confocal microscope images of 934 
RPE cells stably expressing GFP-OPTN E50K (green) and immunostained with a p-TBK1(i; 935 
red) or HA antibody (ii-vi; red). Scale bar, 20 µm. 936 
Figure 7 – The LUBAC complex is recruited to foci. 937 
(A) Confocal microscope images of RPE cells stably expressing GFP-OPTN (green) and 938 
3xHA-HOIP and treated with poly(I:C) for 0 hours and 24 hours. Cells were immunostained 939 
with a HA antibody (red) and Hoechst to label DNA (blue). Scale bar, 20 µm. (B) Pearson’s 940 
correlation coefficient calculated for GFP-OPTN versus HOIP after treatment with poly(I:C) 941 
for 0 and 24 hours. Bars represent the mean of n=3 independent experiments ±s.e.m. Cells 942 
were quantified from ≥5 randomly selected fields of view (1-2 cells/image). Statistical 943 
significance was calculated by one-way ANOVA and a Bonferroni post-hoc test. * = p<0.05 & 944 
** = p<0.01. (C) Confocal microscope images of RPE cells stably expressing GFP-OPTN 945 
(green) and HOIL1-HA (top) or SHARPIN-HA (bottom) and treated with poly(I:C) for 24 946 
hours. Cells were immunostained with a HA antibody (red) and Hoechst to label DNA (blue). 947 
Scale bar, 20 µm. (D) Immunoblot of GFP immunoprecipitations from HEK293T transiently 948 
transfected with GFP, GFP-OPTN wild-type (WT), E50K and E478G probed with GFP and 949 
HA antibodies. (E) Graphs of HOIP mRNA expression [i], NF-κB luciferase activity [ii] and 950 
CXCL8 [iii] and IL6 secretion [iv] in RPE cells transfected with mock or HOIP siRNA and 951 
treated with poly(I:C) for 24 hours. Bars depict mean of n=3 independent experiments 952 
±s.e.m. Statistical significance was determined by two-sample t-test. * = p<0.05, ** = p<0.01. 953 
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(F) Confocal microscope images of RPE cells stably expressing GFP-OPTN (green) and HA-954 
NEMO. Cells were treated with poly(I:C) for 24 hours and immunostained with a HA antibody 955 
(red) and Hoechst to label DNA (blue). Scale bar, 20 µm. (G) Confocal microscope images 956 
of RPE cells stably expressing GFP-OPTN (green) and treated with poly(I:C) for 24 hours. 957 
Cells were immunostained with anti-ATG9A (red) and anti-ubiquitin (clone FK2; blue) 958 
antibodies. Scale bar, 20 µm. 959 
 960 
Figure 8 – OPTN mutations regulate innate immune signalling and cytokine secretion. 961 
(A) Relative NF-κB luciferase activity in RPE cells expressing an NF-κB luciferase reporter, 962 
coexpressing GFP-OPTN E50K and E478G and stimulated with poly(I:C) as indicated. 963 
Graphs depicts mean of n=6 independent experiments ±s.e.m. Statistical significance was 964 
calculated by one-way ANOVA and a Bonferroni post-hoc test. * = p<0.05 and ** = p<0.01. 965 
(B-C) CXCL8 (B) and IL6 (C) secretion from RPE cells expressing GFP-OPTN E50K and 966 
E478G and stimulated with poly(I:C) as indicated. Graphs depicts mean of n=6 independent 967 
experiments ±s.e.m. Statistical significance was calculated by one-way ANOVA and a 968 
Bonferroni post-hoc test. ** = p<0.01, *** = p<0.001 and **** = p<0.0001. (D) Western blots 969 
of lysates from RPE cells expressing GFP-OPTN E50K or E478G, stimulated with poly(I:C) 970 
and probed with the indicated antibodies. (E) IFNa/b secretory levels from RPE cells 971 
coexpressing GFP-OPTN E50K and E478G and stimulated with poly(I:C) for 6 hours 972 
determined from luciferase activity induced in the ISRE-reporter cell line 3C11. Graph 973 
depicts mean of n=5 independent experiments ±s.e.m. Statistical significance was calculated 974 
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SI Figure Legends 
 
Figure S1 – Composition of OPTN foci. 
(A) Confocal microscope images of RPE cells stably expressing GFP-OPTN (green) and 
treated with 2’,3’-cGAMP, LPS and Pam3CSK4 for 24 hours. Cells were stained with 
Hoechst to label DNA (blue). Scale bar, 20 µm. (B) Confocal microscope images of RPE 
cells stably expressing GFP-OPTN (green) and treated with poly(I:C) for 24 hours. Cells 
were immunostained with antibodies (red) against EEA1 (i), LAMP1 (ii), LC3 (iii) and CIMPR 
(iv) and Hoechst was used to visual DNA (blue). Scale bars, 20 µm. Graphs depict pixel 
intensity in green (OPTN) and red (EEA1, LAMP1, LC3 and CIMPR) channels along line 
profiles highlighted in image. (C) Confocal microscope images of RPE cells stably 
expressing GFP-OPTN (green) and treated with poly(I:C) for 24 hours. Cells were 
immunostained with a MYO6 antibody (red) and Hoechst was used to visual DNA (blue). 
Scale bar, 20 µm. Graph depicts Pearson’s correlation coefficient calculated for GFP-OPTN 
versus MYO6 after treatment with poly(I:C) for 0 and 24 hours. Bars represent the mean of 
n=3 independent experiments ±SEM. Cells were quantified from ≥20 randomly selected 
fields of view (1 cell/image). Statistical significance was calculated using a two-sample t-test. 
** = p<0.01. (D) Confocal microscope images of RPE cells stably expressing GFP-OPTN 
(green) and treated with mock (upper panels) or MYO6 (lower panels) siRNA were 
stimulated with vehicle (left column) or poly(I:C) (right column). DNA was labelled with 
Hoechst (blue). Scale bar, 20 µm. 
 
Figure S2 – TLR3 knockdown perturbs foci formation. 
(A) Confocal microscope images of RPE cells stably expressing mCherry-OPTN (red) and 
TLR3-CFP treated with poly(I:C) for 0 hours or 24 hours. Cells were immunostained with a 
GFP antibody to detect TLR3-CFP (green) and Hoechst to label DNA (blue). Scale bars, 20 
µm. (B) Graph depicting relative TLR3 mRNA expression in RPE dCas9-KRAB cells 
expressing a non-targeting sgRNA (NT) or a sgRNA targeting TLR3. Bar represents the 
mean from experiments with two different qPCR primers ±SEM. (C) Widefield microscope 
images of RPE dCas9-KRAB cells stably expressing GFP-OPTN and NT or TLR3 sgRNAs. 
Cells were treated for 0 hours or 24 hours with poly(I:C) and stained with Hoechst to label 
DNA (blue). Scale bar, 20 µm. (D) Percentage of NT or TLR3 sgRNA-expressing GFP-
OPTN cells containing foci after poly(I:C) treatment. Cells were manually counted from ³5 
randomly selected fields of view across n=3 independent experiments ±SEM. Statistical 
significance was determined by repeated measures ANOVA and Bonferroni post-hoc test. ** 
= p<0.01. 
 
Figure S3 – Characterisation of OPTN BioID cells. 
(A) Confocal microscope images of RPE cells stably expressing myc-BirA*-OPTN (upper 
panels) and OPTN-BirA*-HA (lower panels). Cells were immunostained with an anti-myc 
antibody (green), biotin was visualised with fluorescently-labelled streptavidin (red) and DNA 
with Hoechst (blue). Scale bar, 20 µm. (B) Immunoblot analysis of lysates from myc-BirA*-
OPTN or OPTN-BirA*-HA RPE cells probed with myc or HA antibodies respectively. 
 
Figure S4 – OPTN foci are ubiquitinated but don’t require HOIP activity. 
(A) Confocal microscope images of RPE cells stably expressing GFP-OPTN E50K (green) 
and HA-HOIP (blue) immunostained with anti-ATG9A (red; top panel) or anti-ubiquitin (clone 
FK2; red; bottom panel) and HA antibodies (blue). Scale bar, 20 µm. (B) Confocal 
microscope images of RPE cells stably expressing GFP-OPTN (green) and RFP-UBAN (top) 
and RFP-UBAN F312A (bottom; red) and stimulated with poly(I:C) for 24 hours. Scale bar, 
20 µm. (C) Confocal microscope images of RPE cells stably expressing GFP-OPTN (green) 
and treated with mock or HOIP siRNA were stimulated with vehicle or poly(I:C). DNA was 
labelled with Hoechst (blue). Scale bar, 20 µm. Mock-treated condition same as shown in 
Figure S1. (D) Confocal microscope images of RPE cells stably expressing GFP-OPTN 
(green) and transiently transfected with HA-Ub K63. Cells were treated with poly(I:C) for 24 
hours and immunostained with a HA antibody (red) and Hoechst to label DNA (blue). Scale 
bar, 20 µm. 
 
Figure S5 – OPTN mutants also modulate RIG-I-induced cytokine secretion and basal 
cytokine release in RPE cells. 
(A) CXCL8 and (B) IL6 secretion from RPE cells expressing GFP-OPTN wild-type, E50K 
and E478G and stimulated with the RIG-I ligand pppRNA (10 µg/ml) for 24 hours. Graphs 
depicts mean of n=3 independent experiments ±sem. (C) CXCL8 and (D) IL6 release from 
unstimulated RPE cells over a 24 hour period. Graphs depict mean of n=6 ±sem. Statistical 
significance was calculated by one-way ANOVA and a Bonferroni post-hoc test. * = p<0.05, 
** = p<0.01 and *** = p<0.001. 
 
Table S1 – Differential secretion analysis of RPE1 secretome -/+ poly(I:C). Gene IDs, log 
fold-change (FC) and p-value scores are provided. 
 
Table S2 – OPTN BioID data. Gene IDs, fold-change (FC-B) scores and spectral counts 
from BirA*-OPTN and BirA* only RPE1 pull downs are provided. 
 
Table S3 – OPTN BioID data. Gene IDs, fold-change (FC-B) scores and spectral counts 
from OPTN-BirA* and BirA* only RPE1 pull downs are provided. 





